BR112015019339A2 - Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico - Google Patents

Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico

Info

Publication number
BR112015019339A2
BR112015019339A2 BR112015019339A BR112015019339A BR112015019339A2 BR 112015019339 A2 BR112015019339 A2 BR 112015019339A2 BR 112015019339 A BR112015019339 A BR 112015019339A BR 112015019339 A BR112015019339 A BR 112015019339A BR 112015019339 A2 BR112015019339 A2 BR 112015019339A2
Authority
BR
Brazil
Prior art keywords
glycosylated
composition
epithelial cells
mammary gland
human mammal
Prior art date
Application number
BR112015019339A
Other languages
English (en)
Portuguese (pt)
Inventor
M Meade Harry
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BR112015019339A2 publication Critical patent/BR112015019339A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/102—Caprine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015019339A 2013-02-13 2014-02-13 Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico BR112015019339A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361764446P 2013-02-13 2013-02-13
PCT/IB2014/000867 WO2014125382A2 (en) 2013-02-13 2014-02-13 Cetuximab with modified glycosylation and uses thereof

Publications (1)

Publication Number Publication Date
BR112015019339A2 true BR112015019339A2 (pt) 2017-08-22

Family

ID=50980328

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019339A BR112015019339A2 (pt) 2013-02-13 2014-02-13 Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico

Country Status (13)

Country Link
US (1) US20160002330A1 (https=)
EP (1) EP2956484B1 (https=)
JP (1) JP2016513105A (https=)
KR (1) KR20150145225A (https=)
CN (1) CN105358577A (https=)
AR (1) AR094779A1 (https=)
AU (1) AU2014217569B2 (https=)
BR (1) BR112015019339A2 (https=)
CA (1) CA2900915A1 (https=)
IL (1) IL240442A0 (https=)
MX (1) MX2015010429A (https=)
TW (1) TW201444871A (https=)
WO (1) WO2014125382A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3016729B1 (fr) 2013-07-05 2020-03-25 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Matrice de chromatographie d'affinité
US10344285B2 (en) 2014-04-09 2019-07-09 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CA3001312A1 (en) 2015-10-08 2017-04-13 Dna2.0, Inc. Dna vectors, transposons and transposases for eukaryotic genome modification
US20170247458A1 (en) * 2016-01-10 2017-08-31 Sorrento Therapeutics, Inc. Safety for Treating Cancers with a Glycosylated Chimeric Antibody to EGFR
CN116333130A (zh) * 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
KR102376545B1 (ko) * 2017-08-01 2022-03-21 삼성디스플레이 주식회사 플렉시블 디스플레이 윈도우
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2022148549A1 (en) 2020-01-14 2022-07-14 Babylat Gmbh Apparatus and method for obtaining protein-enriched fractions from breast milk

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
CN1668187A (zh) * 2002-05-17 2005-09-14 赫马技术有限公司 能够产生人抗体的转基因有蹄动物
CA2506629A1 (en) * 2002-11-27 2004-06-17 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
CA2450289A1 (en) * 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
KR20140133958A (ko) 2005-10-21 2014-11-20 엘에프비 유에스에이, 인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
FR2901707B1 (fr) * 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
EP3539981A1 (en) * 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
WO2008101177A2 (en) * 2007-02-16 2008-08-21 University Of Virginia Patent Foundation Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
KR20110119702A (ko) * 2009-01-22 2011-11-02 모멘타 파머슈티컬스 인코포레이티드 Ｃｈｏ 세포에서 유도된 글리코단백질 생성물에서의 갈락토오스-알파-1,3-갈락토오스-함유 ｎ-글리칸
ES2605677T3 (es) * 2009-11-11 2017-03-15 Momenta Pharmaceuticals, Inc. Glucosiltransferasa de hámster chino y métodos relacionados

Also Published As

Publication number Publication date
MX2015010429A (es) 2016-05-16
EP2956484A2 (en) 2015-12-23
TW201444871A (zh) 2014-12-01
AR094779A1 (es) 2015-08-26
IL240442A0 (en) 2015-09-24
KR20150145225A (ko) 2015-12-29
US20160002330A1 (en) 2016-01-07
AU2014217569B2 (en) 2018-10-25
AU2014217569A1 (en) 2015-08-27
CA2900915A1 (en) 2014-08-21
JP2016513105A (ja) 2016-05-12
WO2014125382A3 (en) 2014-11-06
WO2014125382A2 (en) 2014-08-21
EP2956484B1 (en) 2018-11-14
CN105358577A (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
BR112015019339A2 (pt) Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico
BR112015019341A2 (pt) Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
BR112015019343A2 (pt) Anticorpo anti-her2, composição, método para produção de uma população de anticorpos, células epiteliais das glândulas mamárias, e, mamífero não humano transgênico
CR20150329A (es) Inmunoglobulinas heterodiméricas
CR20140279A (es) Proteínas que pueden unirse a la il-1
MX374976B (es) Anticuerpos y metodos de uso.
PL2948477T3 (pl) Konstrukty przeciwciała dla cdh19 i cd3
CL2015000582A1 (es) Anticuerpos anti-mcam y métodos asociados de uso
EA201592205A1 (ru) Строительная панель, имеющая повышенную прочность фиксации, и способ изготовления данной панели
BR112015025709A2 (pt) monoterapia com gla para uso em tratamento de câncer
HUE057521T2 (hu) Készítmények és eljárások epithelialis õssejtek szaporítására és tenyésztésére
EP2724338A4 (en) SIGNAL IMPROVEMENT BEAM FORMATION IN A REALITY ENVIRONMENT
EA201590549A1 (ru) Стимуляция развития овариального фолликула и созревания ооцита
PE20160465A1 (es) Panel de yeso producido mediante una alta relacion de agua con respecto a estuco
EP3803481C0 (en) WAVEGUIDE AND RELATED IMPROVEMENTS
DK3041949T3 (da) Celler, der producerer fc-holdige molekyler med modificerede glycosyleringsmønstre, og fremgangsmåder og anvendelser deraf
WO2014140927A8 (en) Proteins with modified glycosylation and methods of production thereof
MX2016005123A (es) Productos de yeso que comprenden gel de silice.
FR2979641B1 (fr) Bandeau de securite et document qui en est pourvu
BR112016014804A2 (pt) Método para produzir heparina, mamífero não humano transgênico, células epiteliais mamárias, heparina, e, composição
EP2977203A4 (en) LONG THINNER GLASS BODY
IL264811B1 (en) Methods for treating an immune disorder-related disease by reducing autoreactivity in a t cell compartment
GB201016616D0 (en) Method and system for determining characteristics of an embryo and uses thereof
MX382786B (es) Uso de monensina para regular la glicosilacion de proteinas recombinantes.
MX363693B (es) Metodos para determinar el pronostico de cancer colorrectal.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements